Psychotic-Like Experiences and Concurrent Substance Use Among People Who Use New Psychoactive Substances

References

• Acciavatti, T., Lupi, M., Santacroce, R., Aguglia, A., Attademo, L., Bandini, L., Ciambrone, P., Lisi, G., Migliarese, G., Pinna, F., Quattrone, D., Ribolsi, M., Signorelli, M. S., Calò, S., Schifano, F., Giannantonio, M., & Martinotti, G. (2017). Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. Human Psychopharmacology, 32(3), e2578. https://doi.org/10.1002/hup.2578
   Web of Science ®Google Scholar
• Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 113, 179–189. https://doi.org/10.1016/j.neubiorev.2020.03.017
   PubMed Web of Science ®Google Scholar
• Archer, J. R. H., Dargan, P. I., Wood, D. M., & Winstock, A. R. (2013). Hospital and prehospital emergency service utilisation as an impact of acute recreational drug and ethanol toxicity. Journal of Substance Use, 18(2), 129–137. https://doi.org/10.3109/14659891.2012.707283
   Web of Science ®Google Scholar
• Arendt, M., Rosenberg, R., Foldager, L., Perto, G., & Munk-Jørgensen, P. (2005). Cannabis-induced psychosis and subsequent schizo­phrenia-spectrum disorders: Follow-up study of 535 incident cases. The British Journal of Psychiatry, 187(6), 510–515. https://doi.org/10.1192/bjp.187.6.510
   PubMedGoogle Scholar
• Arunogiri, S., Foulds, J. A., McKetin, R., & Lubman, D. I. (2018). A systematic review of risk factors for methamphetamine-associated psychosis. The Australian and New Zealand Journal of Psychiatry, 52(6), 514–529. https://doi.org/10.1177/0004867417748750
   PubMed Web of Science ®Google Scholar
• Barratt, M. J., Cakic, V., & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32(2), 141–146. https://doi.org/10.1111/j.1465-3362.2012.00519.x
   PubMed Web of Science ®Google Scholar
• Bassir Nia, A., Medrano, B., Perkel, C., Galynker, I., & Hurd, Y. L. (2016). Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. Journal of Psychopharmacology (Oxford, England), 30(12), 1321–1330. https://doi.org/10.1177/0269881116658990
   PubMed Web of Science ®Google Scholar
• Bennett, K. H., Hare, H. M., Waller, R. M., Alderson, H. L., & Lawrie, S. (2017). Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: A retrospective cross-sectional analysis following public health interventions. BMJ Open, 7(12), e015716. https://doi.org/10.1136/bmjopen-2016-015716
   PubMed Web of Science ®Google Scholar
• Bersani, G., & Prevete, E. (2017). Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases. Human Psychopharmacology, 32(3), e2591–n/a. https://doi.org/10.1002/hup.2591
   Google Scholar
• Betzler, F., Ernst, F., Helbig, J., Viohl, L., Roediger, L., Meister, S., Romanczuk-Seiferth, N., Heinz, A., Ströhle, A., & Köhler, S. (2019). Substance use and prevention programs in Berlin’s party scene: Results of the SuPrA-study. European Addiction Research, 25(6), 283–292. https://doi.org/10.1159/000501310
   PubMed Web of Science ®Google Scholar
• Carrà, G., Bartoli, F., Brambilla, G., Crocamo, C., & Clerici, M. (2015). Comorbid addiction and major mental illness in Europe: A narrative review. Substance Abuse, 36(1), 75–81. https://doi.org/10.1080/08897077.2014.960551
   PubMed Web of Science ®Google Scholar
• Carrà, G., Scioli, R., Monti, M. C., & Marinoni, A. (2006). Severity profiles of substance-abusing patients in Italian community addiction facilities: Influence of psychiatric concurrent disorders. European Addiction Research, 12(2), 96–101. https://doi.org/10.1159/000090429
   PubMed Web of Science ®Google Scholar
• Curran, C., Byrappa, N., & McBride, A. (2004). Stimulant psychosis: Systematic review. The British Journal of Psychiatry, 185(3), 196–204. https://doi.org/10.1192/bjp.185.3.196
   PubMedGoogle Scholar
• Degenhardt, L., Hall, W., Korten, A., & Jablensky, A. (2005). Use of a brief screening instrument for psychosis: Results of an ROC analysis (NDARC Technical Report No. 210). National Drug and Alcohol Research Centre, University of New South Wales.
   Google Scholar
• Deng, H., Verrico, C. D., Kosten, T. R., & Nielsen, D. A. (2018). Psychosis and synthetic cannabinoids. Psychiatry Research, 268, 400–412. https://doi.org/10.1016/j.psychres.2018.08.012
   PubMed Web of Science ®Google Scholar
• Denissoff, A., Mustonen, A., Miettunen, J., Alakokkare, A. E., Veijola, J., Scott, J. G., Sami, M. B., & Niemelä, S. (2022). Trajectories of adolescent psychotic-like experiences and early cannabis exposure: Results from a Finnish Birth Cohort Study. Schizophrenia Research, 246, 95–102. https://doi.org/10.1016/j.schres.2022.06.014
   PubMed Web of Science ®Google Scholar
• Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., Sedefov, R., & Dargan, P. I., Euro-DEN Research Group. (2015). Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clinical Toxicology, 53(9), 893–900. https://doi.org/10.3109/15563650.2015.1088157
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2017). High-risk drug use and new psychoactive substances. EMCDDA Rapid Communication. Publications Office of the European Union. www.emcdda.europa.eu/system/files/publications/4540/TD0217575ENN.pdf
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2020). European Drug Report 2020: Trends and developments. Publications Office of the European Union.
   Google Scholar
• Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157. https://doi.org/10.1016/j.drugalcdep.2011.01.012
   PubMed Web of Science ®Google Scholar
• Ghent University. (n.d). Bioinformatics and evolutionary genomics: Calculate and draw custom Venn diagrams. https://bioinformatics.psb.ugent.be/webtools/Venn/
   Google Scholar
• Giné, C. V., Espinosa, I. F., & Vilamala, M. V. (2014). New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Testing and Analysis, 6(7–8), 819–824. https://doi.org/10.1002/dta.1610
   PubMed Web of Science ®Google Scholar
• Granö, N., Karjalainen, M., Itkonen, A., Anto, J., Edlund, V., Heinimaa, M., & Roine, M. (2011). Differential results between self-report and interview-based ratings of risk symptoms of psychosis. Early Intervention in Psychiatry, 5(4), 309–314. https://doi.org/10.1111/j.1751-7893.2011.00266.x
   PubMed Web of Science ®Google Scholar
• Heinimaa, M., Salokangas, R. K. R., Ristkari, T., Plathin, M., Huttunen, J., Ilonen, T., Suomela, T., Korkeila, J., & Mcglashan, T. H. (2003). PROD-screen – A screen for prodromal symptoms of psychosis. International Journal of Methods in Psychiatric Research, 12(2), 92–104. https://doi.org/10.1002/mpr.146
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction, 108(3), 534–544. https://doi.org/10.1111/j.1360-0443.2012.04078.x
   PubMed Web of Science ®Google Scholar
• Hinterbuchinger, B., & Mossaheb, N. (2021). Psychotic-like experiences: A challenge in definition and assessment. Frontiers in Psychiatry, 12, 582392–582392. https://doi.org/10.3389/fpsyt.2021.582392
   PubMed Web of Science ®Google Scholar
• Hobbs, M., Kalk, N. J., Morrison, P. D., & Stone, J. M. (2018). Spicing it up – Synthetic cannabinoid receptor agonists and psychosis – A systematic review. European Neuropsychopharmacology, 28(12), 1289–1304. https://doi.org/10.1016/j.euroneuro.2018.10.004
   PubMed Web of Science ®Google Scholar
• Hobbs, M., Patel, R., Morrison, P. D., Kalk, N., & Stone, J. M. (2020). Synthetic cannabinoid use in psychiatric patients and relationship to hospitalisation: A retrospective electronic case register study. Journal of Psychopharmacology, 34(6), 648–653. https://doi.org/10.1177/0269881120907973
   PubMed Web of Science ®Google Scholar
• Isaksson, J., Angenfelt, M., Frick, M. A., Olofsdotter, S., & Vadlin, S. (2022). Psychotic-like experiences from adolescence to adulthood: A longitudinal study. Schizophrenia Research, 248, 1–7. https://doi.org/10.1016/j.schres.2022.07.010
   PubMed Web of Science ®Google Scholar
• Joseph, A., Lekas, H., Manseau, M., & Lewis, C. (2019). A polydrug and psychosocial profile of synthetic cannabinoid use in a New York City community sample, 2016-2017. Substance Use & Misuse, 54(2), 282–287. https://doi.org/10.1080/10826084.2018.1517178
   PubMed Web of Science ®Google Scholar
• Manseau, M. W., Rajparia, A., Joseph, A., Azarchi, S., Goff, D., Satodiya, R., & Lewis, C. F. (2017). Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Substance Use & Misuse, 52(6), 822–825. https://doi.org/10.1080/10826084.2016.1263663
   PubMed Web of Science ®Google Scholar
• Marconi, A., Forti, M. D., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. https://doi.org/10.1093/schbul/sbw003
   PubMed Web of Science ®Google Scholar
• Martinotti, G., Lupi, M., Acciavatti, T., Cinosi, E., Santacroce, R., Signorelli, M. S. a., Bandini, L., Lisi, G., Quattrone, D., Ciambrone, P., Aguglia, A., Pinna, F., Calò, S., Janiri, L., & di Giannantonio, M. (2014). Novel psychoactive substances in young adults with and without psychiatric comorbidities. BioMed Research International, 2014, 815424. https://doi.org/10.1155/2014/815424
   PubMed Web of Science ®Google Scholar
• Martinotti, G., Negri, A., Schiavone, S., Montemitro, C., Vannini, C., Baroni, G., Pettorruso, M., De Giorgio, F., Giorgetti, R., Verrastro, V., Trabace, L., Garcia, A., Castro, I., Iglesias Lopez, J., Merino Del Villar, C., Schifano, F., & di Giannantonio, M. (2020). Club drugs: Psychotropic effects and psychopathological characteristics of a sample of inpatients. Frontiers in Psychiatry, 11, 879. https://doi.org/10.3389/fpsyt.2020.00879
   PubMed Web of Science ®Google Scholar
• Martinotti, G., Santacroce, R., Papanti, D., Elgharably, Y., Prilutskaya, M., & Corazza, O. (2017). Synthetic cannabinoids: Psychopharmacology, clinical aspects, psychotic onset. CNS & Neurological Disorders Drug Targets, 16(5), 567–575. https://doi.org/10.2174/1871527316666170413101839
   PubMed Web of Science ®Google Scholar
• Matsumoto, T., Tachimori, H., Tanibuchi, Y., Takano, A., & Wada, K. (2014). Clinical features of patients with designer-drug-related disorder in Japan: A comparison with patients with methamphetamine- and hypnotic/anxiolytic-related disorders. Psychiatry and Clinical Neurosciences, 68(5), 374–382. https://doi.org/10.1111/pcn.12140
   PubMed Web of Science ®Google Scholar
• McKetin, R., Lubman, D. I., Baker, A. L., Dawe, S., & Ali, R. L. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry, 70(3), 319–324. https://doi.org/10.1001/jamapsychiatry.2013.283
   PubMed Web of Science ®Google Scholar
• Miettunen, J., Törmänen, S., Murray, G. K., Jones, P. B., Mäki, P., Ebeling, H., Moilanen, I., Taanila, A., Heinimaa, M., Joukamaa, M., & Veijola, J. (2008). Association of cannabis use with prodromal symptoms of psychosis in adolescence. The British Journal of Psychiatry, 192(6), 470–471. https://doi.org/10.1192/bjp.bp.107.045740
   PubMed Web of Science ®Google Scholar
• Monte, A. A., Calello, D. P., Gerona, R. R., Hamad, E., Campleman, S. L., Brent, J., Wax, P., & Carlson, R. G., ACMT Toxicology Investigators Consortium (ToxIC). (2017). Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: A ToxIC database study. Journal of Medical Toxicology, 13(2), 146–152. https://doi.org/10.1007/s13181-017-0605-9
   PubMed Web of Science ®Google Scholar
• Mustonen, A., Niemelä, S., Nordström, T., Murray, G. K., Mäki, P., Jääskeläinen, E., & Miettunen, J. (2018). Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. The British Journal of Psychiatry, 212(4), 227–233. https://doi.org/10.1192/bjp.2017.52
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
   PubMed Web of Science ®Google Scholar
• Palomäki, J., Therman, S., Kerkelä, M., Järvelin, M. R., Jones, P., Murray, G. K., Nordström, T., Heinimaa, M., Miettunen, J., Veijola, J., & Riekki, T. (2023). Specific adolescent prodromal symptoms associated with onset of psychosis in the Northern Finland Birth Cohort 1986. Early Intervention in Psychiatry, 17(7), 692–701. https://doi.org/10.1111/eip.13363
   PubMed Web of Science ®Google Scholar
• Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., Impagnatiello, M., Pascolo-Fabrici, E., & Bonavigo, T. (2013). “Spiceophrenia”: A systematic overview of “Spice”-related psychopathological issues and a case report. Human Psychopharmacology, 28(4), 379–389. https://doi.org/10.1002/hup.2312
   PubMed Web of Science ®Google Scholar
• Peacock, A., Bruno, R., Gisev, N., Degenhardt, L., Hall, W., Sedefov, R., White, J., Thomas, K. V., Farrell, M., & Griffiths, P. (2019). New psychoactive substances: Challenges for drug surveillance, control, and public health responses. Lancet, 394(10209), 1668–1684. https://doi.org/10.1016/S0140-6736(19)32231-7
   PubMed Web of Science ®Google Scholar
• Riederer, A. M., Campleman, S. L., Carlson, R. G., Boyer, E. W., Manini, A. F., Wax, P. M., & Brent, J. A., Toxicology Investigators Consortium (ToxIC). (2016). Acute poisonings from synthetic cannabinoids – 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010–2015. MMWR. Morbidity and Mortality Weekly Report, 65(27), 692–695. https://doi.org/10.15585/mmwr.mm6527a2
   PubMed Web of Science ®Google Scholar
• Rinaldi, R., Bersani, G., Marinelli, E., & Zaami, S. (2020). The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. Human Psychopharmacology, 35(3), e2727. https://doi.org/10.1002/hup.2727
   PubMed Web of Science ®Google Scholar
• Romanek, K., Stenzel, J., Schmoll, S., Schrettl, V., Geith, S., Eyer, F., & Rabe, C. (2017). Synthetic cathinones in Southern Germany – Characteristics of users, substance-patterns, co-ingestions, and complications. Clinical Toxicology (Philadelphia, Pa.), 55(6), 573–578. https://doi.org/10.1080/15563650.2017.1301463
   PubMed Web of Science ®Google Scholar
• Salokangas, R. K., Heinimaa, M., Svirskis, T., Laine, T., Huttunen, J., Ristkari, T., Ilonen, T., Korkeila, J., Vaskelainen, L., Rekola, J., Hietala, J., Klosterkötter, J., Ruhrmann, S., Graf von Reventlow, H., Linszen, D., Dingemans, P., Birchwood, M., & Patterson, P., EPOS Group. (2009). Perceived negative attitude of others as an early sign of psychosis. European Psychiatry, 24(4), 233–238. https://doi.org/10.1016/j.eurpsy.2008.12.011
   PubMed Web of Science ®Google Scholar
• Scherbaum, N., Seiffert, F., Schifano, F., Specka, M., Bonnet, U., & Bender, S. (2021). High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 111, 110144. https://doi.org/10.1016/j.pnpbp.2020.110144
   PubMed Web of Science ®Google Scholar
• Schifano, F., Napoletano, F., Arillotta, D., Zangani, C., Gilgar, L., Guirguis, A., Corkery, J. M., & Vento, A. (2020). The clinical challenges of synthetic cathinones. British Journal of Clinical Pharmacology, 86(3), 410–419. https://doi.org/10.1111/bcp.14132
   PubMed Web of Science ®Google Scholar
• Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021). New/emerging psychoactive substances and associated psychopathological consequences. Psychological Medicine, 51(1), 43. https://doi.org/10.1017/S003329171900254X
   PubMed Web of Science ®Google Scholar
• Shalit, N., Barzilay, R., Shoval, G., Shlosberg, D., Mor, N., Zweigenhaft, N., Weizman, A., & Krivoy, A. (2016). Characteristics of synthetic cannabinoid and cannabis users admitted to a psychiatric hospital: A comparative study. The Journal of Clinical Psychiatry, 77(8), e989–e995. https://doi.org/10.4088/JCP.15m09938
   PubMed Web of Science ®Google Scholar
• Smith, K. E., Bunting, A. M., Staton, M., Walker, R., Shalash, S., Winston, E., & Pangburn, K. (2017). Examination of synthetic cannabinoid and cathinone use among a drug-using offender sample, 2013-2015. Journal of Psychoactive Drugs, 49(5), 436–445. https://doi.org/10.1080/02791072.2017.1361560
   PubMed Web of Science ®Google Scholar
• Stanley, J. L., Mogford, D. V., Lawrence, R. J., & Lawrie, S. M. (2016). Use of novel psychoactive substances by inpatients on general adult psychiatric wards. BMJ Open, 6(5), e009430. https://doi.org/10.1136/bmjopen-2015-009430
   PubMed Web of Science ®Google Scholar
• Stiles, B. M., Fish, A. F., Cook, C. A., & Silva, V. (2016). Bath salt-induced psychosis: Nursing assessment, diagnosis, treatment, and outcomes. Perspectives in Psychiatric Care, 52(1), 68–78. https://doi.org/10.1111/ppc.12101
   PubMed Web of Science ®Google Scholar
• Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology, 25(11), 1434–1452. https://doi.org/10.1177/0269881110382466
   PubMed Web of Science ®Google Scholar
• Theunissen, E. L., Reckweg, J. T., Hutten, N. R. P. W., Kuypers, K. P. C., Toennes, S. W., Neukamm, M. A., Halter, S., & Ramaekers, J. G. (2022). Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Psychopharmacology, 239(5), 1251–1261. https://doi.org/10.1007/s00213-021-05768-0
   PubMed Web of Science ®Google Scholar
• Vallersnes, O. M., Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., & Dargan, P. I., Euro-DEN Research Group. (2016). Psychosis associated with acute recreational drug toxicity: A European case series. BMC Psychiatry, 16(1), 293. https://doi.org/10.1186/s12888-016-1002-7
   PubMedGoogle Scholar
• Welter, S., Lücke, C., Lam, A. P., Custal, C., Moeller, S., Sörös, P., Thiel, S., Philipsen, A., Müller, H. (2017). Synthetic cannabinoid use in a psychiatric patient population: A pilot study. European Addiction Research, 23(4), 182–193. https://doi.org/10.1159/000479554
   Google Scholar
• Winstock, A. R., & Barratt, M. J. (2013). The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacology, 28(4), 390–393. https://doi.org/10.1002/hup.2292
   PubMed Web of Science ®Google Scholar
• Zammit, S., Kounali, D., Cannon, M., David, A. S., Gunnell, D., Heron, J., Jones, P. B., Lewis, S., Sullivan, S., Wolke, D., & Lewis, G. (2013). Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. The American Journal of Psychiatry, 170(7), 742–750. https://doi.org/10.1176/appi.ajp.2013.12060768
   PubMed Web of Science ®Google Scholar